Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of LY2541546 in postmenopausal women with low bone mineral density
2010-019758-42Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in osteoporosis comparing LY2541546 with Placebo (2 arms). Primary endpoint: Change in lumbar spine BMD at 52 weeks. Started Aug 2010; status: completed.
02
Drugs
blosozumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2010-019758-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019758-42.